Clinical trial NCT06561581: Acuity Functional Impact and Implementation Outcomes Evaluation
Official title: Acuity Functional Impact and Implementation Outcomes Evaluation
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Autism
Lead sponsor: Experiad LLC
Sponsor class: INDUSTRY
First posted: 2024-08-20
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study will test feature enhancements to a behavioral therapy data collection software (Motivity) that will add a new clinical decision support module, called Acuity. Acuity is a Quality Improvement (QI) intervention targeted at Behavior Analysts (BAs) and Behavior Technicians (BTs) that aims to improve the delivery of autism behavioral therapy. Subjects will be staff recruited from existing Motivity customers.

Detailed description: Acuity is intended to provide significant improvements in treatment planning, progress tracking, trend monitoring, and dosage management. If successful, Acuity will provide Applied Behavior Analysis (ABA) practitioners with a higher level of real-time insight into their clinical data, enabling more efficient and productive treatment. Research has shown that first-generation systems fall short in supporting overworked BAs who are overwhelmed with data. Acuity will address critical shortfalls by enabling more agile corrective actions and data-driven planning across multiple aspects of treatment, providing practitioners with new levels of rigorous, real-time insight into their clinical data. Acuity will help BAs establish and adhere to realistic treatment timelines, and will proactively alert the BA to noteworthy trends in the data as they occur, such as learner performance issues, missed dosages, and significant changes in tracked behaviors. In doing so, Acuity will support more responsive and effective treatment.

Eligibility criteria: Inclusion Criteria:

* Behavior Analysts and Behavior Technicians treating kids with autism
* Must be employed by one of the autism treatment clinics that have agreed to participate in the study.
* Must be employed by Experiad customers who are using Motivity software as part of their practice.

Exclusion Criteria:

* All people not listed above

Primary outcomes:
measure: Number of participants with improved estimation of Trials to Criterion and Time (days) to Criterion
timeFrame: through study completion, expected to be 18 months from the start of retroactive observation period
measure: Increased frequency of changes to programs and prescribed dosages, resulting in reduced Trials to Criterion and Time to Criterion.
timeFrame: through study completion, expected to be 18 months from the start of retroactive observation period
measure: Increased adherence to prescribed dosage
timeFrame: through study completion, expected to be 18 months from the start of retroactive observation period
measure: Number of participants who find Acuity and its components practical and possible to use, assessed by qualitative measures and system usage tracking
timeFrame: at the end of the study, expected to be 18 months from the start of retroactive observation period
measure: Proportion of clinics and providers that actively use Acuity, assessed by system usage tracking.
timeFrame: at the end of the study, expected to be 18 months from the start of retroactive observation period
measure: Number of BAs & BTs who utilize Acuity as intended to provide learners with accurate treatment plans, and achieve expected results, as measured by system usage and qualitative assessment.
timeFrame: at the end of the study, expected to be 18 months from the start of retroactive observation period
measure: Majority of BAs and BTs rate Acuity and its components as attractive, agreeable, or palatable.
timeFrame: at the end of the study, expected to be 18 months from the start of retroactive observation period
measure: Frequency at which Acuity and its components are rated as suitable, fitting, or proper for achieving the goals set forth in treatment plans, as measured by surveys.
timeFrame: at the end of the study, expected to be 18 months from the start of retroactive observation period
Secondary outcomes:
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Experiad LLC
state: Hawaii
Study officials:
References: